Wolfe Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX)

Stock analysts at Wolfe Research initiated coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $48.00 price target on the stock. Wolfe Research’s price objective would suggest a potential upside of 251.39% from the company’s previous close.

A number of other brokerages have also commented on AVTX. HC Wainwright raised their price target on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price target on shares of Avalo Therapeutics in a research note on Tuesday, March 24th. Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim started coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

Avalo Therapeutics Stock Down 3.9%

Shares of AVTX stock opened at $13.66 on Thursday. The stock has a fifty day moving average of $15.49 and a 200 day moving average of $16.09. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72. The firm has a market capitalization of $311.31 million, a price-to-earnings ratio of -2.38 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. Equities research analysts anticipate that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. This trade represents a 87.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total value of $136,857.00. Following the transaction, the chief financial officer owned 17,338 shares of the company’s stock, valued at $297,346.70. The trade was a 31.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,100 shares of company stock valued at $764,724 in the last three months. Insiders own 3.03% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. BIT Capital GmbH bought a new position in shares of Avalo Therapeutics during the third quarter valued at $25,000. PFS Partners LLC increased its holdings in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Avalo Therapeutics during the third quarter valued at $143,000. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the second quarter valued at $56,000. Finally, Jump Financial LLC bought a new position in shares of Avalo Therapeutics during the fourth quarter valued at $238,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics News Summary

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $48 price target (about a 250% upside vs. the current share price). This is a strong institutional endorsement that can attract buy-side interest and rerate the stock if Wolfe’s clinical/financial thesis gains traction. Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation
• Positive Sentiment: Recent broker coverage shows elevated analyst targets and a moderate-buy consensus (market sources cite ~$42–44 consensus targets), which supports upside expectations from sell-side research. Avalo Therapeutics (NASDAQ:AVTX) Receives $42.25 Consensus Target Price from Brokerages
• Neutral Sentiment: One April 10 data entry reporting “0 shares” shorted appears to be a reporting glitch or NaN error and conflicts with the March 31 short-interest filing; treat that specific datapoint as unreliable until corrected by the exchange.
• Negative Sentiment: Short interest jumped on March 31 to ~5.54M shares (up ~35.5% vs. mid‑March), representing about 25.1% of shares outstanding with a days-to-cover of ~6.2 based on average volume — a significant short base that can weigh on the stock and increase downside pressure and volatility if selling accelerates.
• Negative Sentiment: Insider selling: Director/officer Mittie Doyle sold 3,970 shares on April 6 at ~$18 (part of prior Rule 10b5-1 sales). Repeated insider sales (including earlier larger dispositions) can be interpreted negatively by investors, even if pre‑arranged. SEC filing: SEC Form 4 filing for Mittie Doyle

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.